Search Results

AptarGroup, Inc. announced that following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, it has completed the acquisition of a majority stake in Voluntis from the company’s reference shareholders and certain members of the management.

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics.

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, announced today a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes.

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.

Voluntis (Paris:VTX) (Euronext Paris, Mnemo: VTX - ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software.

Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, today announced it has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Oleena™ software for oncology-related symptoms management and remote patient monitoring. Oleena™ is determined as Class II medical device falling under enforcement discretion per FDA Guidance.

Voluntis announces the release of an upgraded version of Insulia that improves user experience and makes Insulia available in Spanish.

Voluntis and AstraZeneca announced that they have been awarded the 2018 Prix Galien – MedStartUp Award for Best Patient Engagement Technology for eCO.

Voluntis (Paris:VTX) (Euronext Paris, ticker: VTX - ISIN: FR0004183960), a digital therapeutics company, announced today the nominations of Jan Berger, MD, and Roberta Herman, MD, to its Board of Directors

Voluntis announces that results for eCO, the digital therapeutic it developed for women with ovarian cancer in partnership with AstraZeneca and the National Cancer Institute, have been published in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics.